minoxidil has been researched along with Alopecia Circumscripta in 130 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata." | 10.16 | 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988) |
| "Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy." | 9.51 | Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022) |
| "Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking." | 9.51 | Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022) |
| "The therapeutic value of topical minoxidil in alopecia areata (AA) has been investigated in recent years, with variable results." | 9.07 | Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. ( Abdel-Salam, MM; Greenspan, JS; Khoury, EL; Price, VH; Stern, M, 1992) |
| "A 6-week taper of prednisone offers potential for more than 25% regrowth in 30% to 47% of patients with alopecia areata with predictable and transient side effects." | 9.07 | Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. ( Carson, SC; Olsen, EA; Turney, EA, 1992) |
| "Fifty patients with extensive alopecia areata took part in a prolonged double blind trial to compare the effect of 1% minoxidil in unguentum merck with that of unguentum merck alone." | 9.06 | A trial of 1% minoxidil used topically for severe alopecia areata. ( Savin, JA; Vestey, JP, 1986) |
| "Topical minoxidil solution can induce hair regrowth in alopecia areata." | 9.06 | Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. ( Fiedler-Weiss, VC, 1987) |
| "The safety and efficacy of 3% topical minoxidil were evaluated in the treatment of extensive patchy alopecia areata, alopecia totalis, and alopecia universalis." | 9.06 | Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. ( Price, VH, 1987) |
| "This study was conducted to further evaluate the safety and efficacy of 3% topical minoxidil in the treatment of extensive alopecia areata." | 9.06 | Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. ( Price, VH, 1987) |
| "Perhaps the most intriguing aspect of topical minoxidil is the fact that this drug can promote hair growth in two unrelated conditions: alopecia areata (AA) and androgenetic alopecia." | 9.06 | Topical minoxidil in extensive alopecia areata, including 3-year follow-up. ( Price, VH, 1987) |
| "A modified double blind crossover study was performed to assess the effect of 1% topical minoxidil as compared with placebo in 30 patients with alopecia areata and alopecia totalis." | 9.05 | Topical minoxidil in the treatment of alopecia areata. ( Fenton, DA; Wilkinson, JD, 1983) |
| "Topical minoxidil has been used for almost 40 years to treat alopecia." | 9.05 | Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020) |
| "While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions." | 8.31 | Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023) |
| "The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 7.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
| "Medical records of 37 patients with alopecia areata who were started on topical anthralin before age 17 were reviewed for efficacy and safety data." | 7.88 | Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. ( Bergfeld, WF; Ratnaparkhi, R; Wang, S; Wu, SZ, 2018) |
| "Hypertrichosis is a well-recognized adverse effect of therapy with either oral or topical minoxidil." | 7.79 | Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy. ( Ben Hamida, M; Benmously Mlika, R; Dorbani Ben Thabet, I; Hammami, H; Mokhtar, I; Rouatbi, M, 2013) |
| "5% anthralin was used to treat 51 patients with severe treatment-resistant alopecia areata." | 7.68 | Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. ( DeVillez, RL; Fiedler, VC; Metzler, C; Szpunar, GJ; Wendrow, A, 1990) |
| "The mechanism of minoxidil-induced hair regrowth in alopecia areata (AA) is unknown." | 7.67 | Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. ( Buys, CM; Fiedler, VC, 1987) |
| "A 1% minoxidil topical solution was used to treat 48 patients with alopecia areata, ie, 24 patients with patchy disease and 24 patients with alopecia totalis or alopecia universalis." | 7.67 | Alopecia areata treated with topical minoxidil. ( Chambers, DA; Cohen, RL; Cook, B; Fu, TS; Robinson, LA; Weiss, VC; West, DP, 1984) |
| "Mitogen-induced T cell blastogenesis was determined in 47 patients with severe alopecia areata, before and after treatment with topical 5% minoxidil, and compared with control values." | 7.67 | Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. ( Buys, CM; Fiedler-Weiss, VC, 1987) |
| "A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata." | 7.67 | Evaluation of oral minoxidil in the treatment of alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, J; Wendrow, A; West, DP, 1987) |
| " Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects." | 7.11 | Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022) |
| "Alopecia areata is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern." | 6.84 | Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. ( El Taieb, MA; Ibrahim, H; Nada, EA; Seif Al-Din, M, 2017) |
| "The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata." | 6.16 | 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988) |
| "Topical minoxidil has shown some promise for the treatment of male-pattern alopecia and alopecia areata." | 6.16 | Minoxidil. ( Fiedler-Weiss, VC, 1987) |
| "Based on our findings, the mixed preparation of piperine, capsaicin, and curcumin is effective in treating alopecia areata, but it has not been shown to be superior to minoxidil in short-term therapy." | 5.51 | Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata. ( Mao, Y; Mei, X; Shi, W; Song, J; Xie, Y; Xu, Z, 2022) |
| "Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking." | 5.51 | Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata. ( Abdallah, MAE; Shareef, R; Soltan, MY, 2022) |
| "We report a case of a young woman with Kerion Celsi favored by the use of a tretinoin+minoxidil+betametasone valerate lotion." | 5.36 | Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. ( Ascierto, PA; Capuano, A; Di Girolamo, F; Montesarchio, G; Vozza, A; Vozza, G, 2010) |
| "Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface." | 5.36 | Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010) |
| " Currently, the FDA-approved drugs for the treatment of androgenetic alopecia (AGA) are minoxidil and finasteride and immunosuppressives are therapeutic options for alopecia areata (AA), but the objective adverse effects and high cost of these treatments reduce patient compliance and thus the effectiveness of the drugs." | 5.22 | Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds. ( Dou, J; Xu, X; Zhang, X; Zhang, Z, 2022) |
| "A 6-week taper of prednisone offers potential for more than 25% regrowth in 30% to 47% of patients with alopecia areata with predictable and transient side effects." | 5.07 | Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. ( Carson, SC; Olsen, EA; Turney, EA, 1992) |
| "The therapeutic value of topical minoxidil in alopecia areata (AA) has been investigated in recent years, with variable results." | 5.07 | Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. ( Abdel-Salam, MM; Greenspan, JS; Khoury, EL; Price, VH; Stern, M, 1992) |
| "Fifty patients with extensive alopecia areata took part in a prolonged double blind trial to compare the effect of 1% minoxidil in unguentum merck with that of unguentum merck alone." | 5.06 | A trial of 1% minoxidil used topically for severe alopecia areata. ( Savin, JA; Vestey, JP, 1986) |
| "The safety and efficacy of 3% topical minoxidil were evaluated in the treatment of extensive patchy alopecia areata, alopecia totalis, and alopecia universalis." | 5.06 | Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. ( Price, VH, 1987) |
| "This study was conducted to further evaluate the safety and efficacy of 3% topical minoxidil in the treatment of extensive alopecia areata." | 5.06 | Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. ( Price, VH, 1987) |
| "Topical minoxidil solution can induce hair regrowth in alopecia areata." | 5.06 | Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. ( Fiedler-Weiss, VC, 1987) |
| "Perhaps the most intriguing aspect of topical minoxidil is the fact that this drug can promote hair growth in two unrelated conditions: alopecia areata (AA) and androgenetic alopecia." | 5.06 | Topical minoxidil in extensive alopecia areata, including 3-year follow-up. ( Price, VH, 1987) |
| "A modified double blind crossover study was performed to assess the effect of 1% topical minoxidil as compared with placebo in 30 patients with alopecia areata and alopecia totalis." | 5.05 | Topical minoxidil in the treatment of alopecia areata. ( Fenton, DA; Wilkinson, JD, 1983) |
| "Topical minoxidil has been used for almost 40 years to treat alopecia." | 5.05 | Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. ( Atanaskova Mesinkovska, N; Juhasz, M; Michelle, L; Muller Ramos, P; Sharma, AN, 2020) |
| "A double-blind cross over study on the effect of 3 months' treatment with 1% topical minoxidil on 23 individuals with alopecia areata was performed." | 5.05 | Topical minoxidil for extended areate alopecia. ( Frentz, G, 1985) |
| "While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions." | 4.31 | Oral minoxidil use in androgenetic alopecia and telogen effluvium. ( Cooley, JE; Feaster, B; McMichael, AJ; Onamusi, T, 2023) |
| "The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 3.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
| "Medical records of 37 patients with alopecia areata who were started on topical anthralin before age 17 were reviewed for efficacy and safety data." | 3.88 | Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. ( Bergfeld, WF; Ratnaparkhi, R; Wang, S; Wu, SZ, 2018) |
| "Hypertrichosis is a well-recognized adverse effect of therapy with either oral or topical minoxidil." | 3.79 | Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy. ( Ben Hamida, M; Benmously Mlika, R; Dorbani Ben Thabet, I; Hammami, H; Mokhtar, I; Rouatbi, M, 2013) |
| "5% anthralin was used to treat 51 patients with severe treatment-resistant alopecia areata." | 3.68 | Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. ( DeVillez, RL; Fiedler, VC; Metzler, C; Szpunar, GJ; Wendrow, A, 1990) |
| "A 1% minoxidil topical solution was used to treat 48 patients with alopecia areata, ie, 24 patients with patchy disease and 24 patients with alopecia totalis or alopecia universalis." | 3.67 | Alopecia areata treated with topical minoxidil. ( Chambers, DA; Cohen, RL; Cook, B; Fu, TS; Robinson, LA; Weiss, VC; West, DP, 1984) |
| "Mitogen-induced T cell blastogenesis was determined in 47 patients with severe alopecia areata, before and after treatment with topical 5% minoxidil, and compared with control values." | 3.67 | Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. ( Buys, CM; Fiedler-Weiss, VC, 1987) |
| "A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata." | 3.67 | Evaluation of oral minoxidil in the treatment of alopecia areata. ( Buys, CM; Fiedler-Weiss, VC; Rumsfield, J; Wendrow, A; West, DP, 1987) |
| "The mechanism of minoxidil-induced hair regrowth in alopecia areata (AA) is unknown." | 3.67 | Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. ( Buys, CM; Fiedler, VC, 1987) |
| " Topical latanoprost added to therapeutic efficacy of topical betamethason and minoxidil in treating patchy AA, suggesting it being beneficial and safe adjuvant therapy and add to efficacy of topical treatments without any adverse effects." | 3.11 | Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Jafari, M; Yazdanian, N, 2022) |
| "Alopecia areata is an autoimmune disease leading to nonscarring hair loss on the scalp or body." | 3.01 | Treatments for alopecia areata: a network meta-analysis. ( Bennouna-Dalero, T; Correa-Pérez, A; Fernández-García, S; Gaetano Gil, A; Giraldo, L; Mateos-Haro, M; Novoa-Candia, M; Ortega-Quijano, D; Saceda-Corralo, D; Sánchez Vanegas, G; Tomlinson, J; Urueña Rodriguez, MG; Vaño-Galván, S; Zamora, J, 2023) |
| "Alopecia areata is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern." | 2.84 | Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation. ( El Taieb, MA; Ibrahim, H; Nada, EA; Seif Al-Din, M, 2017) |
| "Individuals with hair loss experience a substantial mental burden, which potentially hinders their social life." | 2.82 | Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management. ( Fujita, T; Matsudo, K; Ohyama, M, 2022) |
| "Alopecia areata is a world wide cosmetic problem." | 2.73 | Efficacy of combination therapy for the management regime of Alopecia areata. ( Chowdhury, MM; Rahman, MH; Wahab, MA, 2007) |
| "To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients." | 2.72 | Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. ( Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021) |
| "Androgenetic alopecia was the most common studied condition, but others included telogen effluvium, tractional alopecia, postchemotherapy-induced alopecia, monilethrix, loose anagen hair syndrome, alopecia areata and scarring alopecias (frontal fibrosing alopecia and lichen planopilaris)." | 2.72 | Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. ( Fabbrocini, G; Ocampo-Candiani, J; Ocampo-Garza, SS; Ruggiero, A; Villani, A, 2021) |
| "Alopecia areata is the third most common cause of dermatology consultations in children but the treatment of paediatric alopecia areata remains challenging." | 2.72 | Therapeutic management in paediatric alopecia areata: A systematic review. ( Kołodziejak, M; Olszewska, M; Rakowska, A; Rudnicka, L; Sikora, M; Stochmal, A; Waśkiel-Burnat, A, 2021) |
| " The main side effect was pain due to PRP injection, which disappeared after ending the treatment and only one article reported more serious side effects." | 2.72 | Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. ( Behrangi, E; Ghassemi, M; Goodarzi, A; Najar Nobari, N; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2021) |
| "Three of five patients with androgenic alopecia using 5% minoxidil for 12 months noted hair regrowth, ranging from minimally observable hair to an appreciable restoration of larger, pigmented, terminal hair in one patient." | 2.65 | Topical minoxidil for hair regrowth. ( Case, P; Ellis, CN; Headington, JT; Kang, S; Swanson, NA; Vanderveen, EE; Voorhees, JJ, 1984) |
| "Many therapies are available for the treatment of alopecia areata, including topical, systemic, and injectable modalities." | 2.58 | Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. ( Avila, L; Brinster, N; Christiano, AM; Lo Sicco, K; Shapiro, J; Strazzulla, LC; Wang, EHC, 2018) |
| "Hair loss is not uncommon in the pediatric group, but its patterns in this group are different from those seen in adults." | 2.52 | Hair loss in children. ( Alves, R; Grimalt, R, 2015) |
| "Treatment of alopecia areata is dependent on age of patient as well as the extent and duration of scalp involvement." | 2.49 | Current treatment of alopecia areata. ( Shapiro, J, 2013) |
| "Focal hair loss can be further broken down into scarring and nonscarring." | 2.45 | Diagnosing and treating hair loss. ( Mounsey, AL; Reed, SW, 2009) |
| "Alopecia areata is relatively benign and often resolves on its own, although its psychosocial impact on children and young adults can be severe." | 2.43 | Alopecia areata: what to expect from current treatments. ( Bergfeld, WF; Dombrowski, NC, 2005) |
| "Alopecia areata is an asymptomatic, nonscarring hair loss with spontaneous remissions and exacerbations." | 2.38 | Alopecia areata. ( Weitzner, JM, 1990) |
| "The most common causes of hair loss are androgenetic alopecia (AGA) and telogen effluvium (TE)." | 1.91 | Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia. ( Bruni, F; Caro, G; Cedirian, S; Fortuna, M; Piraccini, BM; Quadrelli, F; Rossi, A; Starace, M, 2023) |
| "We report a case of a young woman with Kerion Celsi favored by the use of a tretinoin+minoxidil+betametasone valerate lotion." | 1.36 | Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. ( Ascierto, PA; Capuano, A; Di Girolamo, F; Montesarchio, G; Vozza, A; Vozza, G, 2010) |
| "Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface." | 1.36 | Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010) |
| "Alopecia areata has never been documented in a newborn." | 1.30 | Congenital alopecia areata. ( de Viragh, PA; Gianadda, B; Levy, ML, 1997) |
| "Until etiology is better understood, treatments for alopecia areata are likely to remain palliative." | 1.27 | Alopecia areata: pathogenesis and treatment. ( Krull, EA; Mitchell, AJ, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (31.54) | 18.7374 |
| 1990's | 15 (11.54) | 18.2507 |
| 2000's | 17 (13.08) | 29.6817 |
| 2010's | 26 (20.00) | 24.3611 |
| 2020's | 31 (23.85) | 2.80 |
| Authors | Studies |
|---|---|
| Praharaj, SK | 1 |
| Munoli, RN | 1 |
| Udupa, ST | 1 |
| Vaidyanathan, S | 1 |
| Nestor, MS | 1 |
| Ablon, G | 1 |
| Gade, A | 1 |
| Han, H | 1 |
| Fischer, DL | 1 |
| Shome, D | 1 |
| Kapoor, R | 1 |
| Doshi, K | 1 |
| Patel, G | 1 |
| Vadera, S | 1 |
| Kumar, V | 1 |
| Moussa, A | 1 |
| Bokhari, L | 1 |
| Sinclair, RD | 1 |
| Feaster, B | 1 |
| Onamusi, T | 1 |
| Cooley, JE | 1 |
| McMichael, AJ | 2 |
| Mao, Y | 1 |
| Xu, Z | 1 |
| Song, J | 1 |
| Xie, Y | 1 |
| Mei, X | 1 |
| Shi, W | 1 |
| de Nicolas-Ruanes, B | 1 |
| Moreno-Arrones, OM | 1 |
| Saceda-Corralo, D | 3 |
| Hermosa-Gelbard, A | 1 |
| Rodrigues-Barata, R | 1 |
| Gil-Redondo, R | 1 |
| Garcia-Mouronte, E | 1 |
| Vañó-Galván, S | 3 |
| Dou, J | 1 |
| Zhang, Z | 1 |
| Xu, X | 1 |
| Zhang, X | 1 |
| Ohyama, M | 1 |
| Matsudo, K | 1 |
| Fujita, T | 1 |
| Toma, DM | 1 |
| Atallah, RB | 1 |
| Eldahshan, RM | 1 |
| Reyes-Hadsall, S | 1 |
| Drake, L | 1 |
| Han, JJ | 1 |
| Lee, KJ | 1 |
| Zhou, G | 1 |
| Mostaghimi, A | 1 |
| Huang, KP | 1 |
| Hu, D | 1 |
| Yang, S | 1 |
| Ghassemi, M | 2 |
| Yazdanian, N | 1 |
| Behrangi, E | 2 |
| Jafari, M | 1 |
| Goodarzi, A | 2 |
| Navarro-Triviño, FJ | 1 |
| Pegalajar-García, MD | 1 |
| Gil-Villalba, A | 1 |
| Ruiz-Villaverde, R | 1 |
| Zhang, J | 1 |
| Lin, P | 1 |
| Lin, H | 1 |
| Ma, C | 1 |
| Hu, Y | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Cedirian, S | 1 |
| Bruni, F | 1 |
| Quadrelli, F | 1 |
| Caro, G | 1 |
| Fortuna, M | 1 |
| Rossi, A | 1 |
| Piraccini, BM | 1 |
| Starace, M | 1 |
| Mateos-Haro, M | 1 |
| Novoa-Candia, M | 1 |
| Sánchez Vanegas, G | 1 |
| Correa-Pérez, A | 1 |
| Gaetano Gil, A | 1 |
| Fernández-García, S | 1 |
| Ortega-Quijano, D | 1 |
| Urueña Rodriguez, MG | 1 |
| Bennouna-Dalero, T | 1 |
| Giraldo, L | 1 |
| Tomlinson, J | 1 |
| Zamora, J | 1 |
| Wambier, CG | 1 |
| Craiglow, BG | 1 |
| King, BA | 1 |
| Li, A | 1 |
| Meng, X | 1 |
| Xing, X | 1 |
| Tan, H | 1 |
| Liu, J | 1 |
| Li, C | 1 |
| Sharma, AN | 1 |
| Michelle, L | 1 |
| Juhasz, M | 1 |
| Muller Ramos, P | 1 |
| Atanaskova Mesinkovska, N | 1 |
| Abdallah, MAE | 1 |
| Shareef, R | 1 |
| Soltan, MY | 1 |
| Hon, KL | 2 |
| Luk, DCK | 1 |
| Leung, AKC | 1 |
| Ng, C | 1 |
| Loo, SKF | 1 |
| Dincer, D | 1 |
| Tanacan, E | 1 |
| Kose Ozkan, C | 1 |
| Hordinsky, MK | 2 |
| Sterkens, A | 1 |
| Lambert, J | 1 |
| Bervoets, A | 1 |
| Roohaninasab, M | 1 |
| Sadeghzadeh-Bazargan, A | 1 |
| Najar Nobari, N | 1 |
| Chien Yin, GO | 1 |
| Siong-See, JL | 1 |
| Wang, ECE | 1 |
| Waśkiel-Burnat, A | 1 |
| Kołodziejak, M | 1 |
| Sikora, M | 1 |
| Stochmal, A | 1 |
| Rakowska, A | 1 |
| Olszewska, M | 1 |
| Rudnicka, L | 1 |
| Fukumoto, T | 1 |
| Fukumoto, R | 1 |
| Magno, E | 1 |
| Oka, M | 1 |
| Nishigori, C | 1 |
| Horita, N | 1 |
| Mirmirani, P | 1 |
| Fu, J | 1 |
| Villani, A | 1 |
| Fabbrocini, G | 2 |
| Ocampo-Candiani, J | 1 |
| Ruggiero, A | 1 |
| Ocampo-Garza, SS | 1 |
| El-Ashmawy, AA | 1 |
| El-Maadawy, IH | 1 |
| El-Maghraby, GM | 1 |
| Murad, A | 1 |
| Bergfeld, W | 1 |
| Strazzulla, LC | 1 |
| Wang, EHC | 1 |
| Avila, L | 1 |
| Lo Sicco, K | 1 |
| Brinster, N | 1 |
| Christiano, AM | 1 |
| Shapiro, J | 6 |
| Gomez-Zubiaur, A | 1 |
| Velez-Velazquez, MD | 1 |
| Wu, SZ | 1 |
| Wang, S | 1 |
| Ratnaparkhi, R | 1 |
| Bergfeld, WF | 2 |
| Cranwell, WC | 1 |
| Lai, VW | 1 |
| Photiou, L | 1 |
| Meah, N | 1 |
| Wall, D | 1 |
| Rathnayake, D | 1 |
| Joseph, S | 1 |
| Chitreddy, V | 1 |
| Gunatheesan, S | 1 |
| Sindhu, K | 1 |
| Sharma, P | 1 |
| Green, J | 1 |
| Eisman, S | 1 |
| Yip, L | 2 |
| Jones, L | 1 |
| Sinclair, R | 2 |
| Napolitano, M | 1 |
| Cantelli, M | 1 |
| Vastarella, M | 1 |
| Nappa, P | 1 |
| Patruno, C | 1 |
| Freire, PCB | 1 |
| Riera, R | 1 |
| Martimbianco, ALC | 1 |
| Petri, V | 1 |
| Atallah, AN | 1 |
| Wang, W | 1 |
| Li, Y | 1 |
| Benmously Mlika, R | 1 |
| Ben Hamida, M | 1 |
| Hammami, H | 1 |
| Dorbani Ben Thabet, I | 1 |
| Rouatbi, M | 1 |
| Mokhtar, I | 1 |
| Rebora, A | 1 |
| Farhangian, ME | 1 |
| Huang, KE | 1 |
| Feldman, SR | 1 |
| Alves, R | 1 |
| Grimalt, R | 1 |
| Perera, E | 1 |
| Emre, S | 1 |
| Metin, A | 1 |
| Caykoylu, A | 1 |
| Akoglu, G | 1 |
| Ceylan, GG | 1 |
| Oztekin, A | 1 |
| Col, ES | 1 |
| El Taieb, MA | 1 |
| Ibrahim, H | 1 |
| Nada, EA | 1 |
| Seif Al-Din, M | 1 |
| Tan, C | 1 |
| Zhu, WY | 1 |
| Min, ZS | 1 |
| Mounsey, AL | 1 |
| Reed, SW | 1 |
| Mukherjee, N | 1 |
| Burkhart, CN | 1 |
| Morrell, DS | 1 |
| Alkhalifah, A | 1 |
| Alsantali, A | 1 |
| Wang, E | 1 |
| McElwee, KJ | 1 |
| Ali, A | 1 |
| Martin, JM | 1 |
| Vozza, A | 1 |
| Di Girolamo, F | 1 |
| Montesarchio, G | 1 |
| Capuano, A | 1 |
| Ascierto, PA | 1 |
| Vozza, G | 1 |
| Haynes, JW | 1 |
| Persons, R | 1 |
| Jamieson, B | 1 |
| Leung, AK | 1 |
| García Llopis, P | 1 |
| Vicente Valor, MI | 1 |
| Martínez Cristóbal, A | 1 |
| Ito, T | 1 |
| Ganzetti, G | 1 |
| Campanati, A | 1 |
| Offidani, A | 1 |
| Thiedke, CC | 1 |
| Trüeb, RM | 1 |
| MacDonald Hull, SP | 1 |
| Wood, ML | 1 |
| Hutchinson, PE | 1 |
| Sladden, M | 1 |
| Messenger, AG | 1 |
| Dombrowski, NC | 1 |
| Kwong, RA | 1 |
| Kossard, S | 1 |
| Georgala, S | 1 |
| Befon, A | 1 |
| Maniatopoulou, E | 1 |
| Georgala, C | 1 |
| Wasserman, D | 1 |
| Guzman-Sanchez, DA | 1 |
| Scott, K | 1 |
| McMichael, A | 1 |
| Khumalo, NP | 1 |
| Ngwanya, RM | 1 |
| Martinelli, PT | 1 |
| Cohen, PR | 1 |
| Schulze, KE | 1 |
| Nelson, B | 1 |
| Chowdhury, MM | 1 |
| Rahman, MH | 1 |
| Wahab, MA | 1 |
| Mitchell, AJ | 1 |
| Krull, EA | 1 |
| Vanderveen, EE | 1 |
| Ellis, CN | 1 |
| Kang, S | 1 |
| Case, P | 1 |
| Headington, JT | 1 |
| Voorhees, JJ | 1 |
| Swanson, NA | 1 |
| De Prost, Y | 2 |
| Paquez, F | 1 |
| Baspeyraz, M | 1 |
| Touraine, R | 1 |
| Fenton, DA | 2 |
| Wilkinson, JD | 2 |
| King, CM | 1 |
| Harrop, B | 1 |
| Dave, VK | 1 |
| Maitland, JM | 1 |
| Aldridge, RD | 1 |
| Main, RA | 1 |
| White, MI | 1 |
| Ormerod, AD | 1 |
| Weiss, VC | 2 |
| West, DP | 3 |
| Fu, TS | 1 |
| Robinson, LA | 1 |
| Cook, B | 1 |
| Cohen, RL | 1 |
| Chambers, DA | 1 |
| Mueller, CE | 1 |
| Tan, J | 1 |
| Ho, V | 1 |
| Tron, V | 1 |
| Epstein, E | 2 |
| Savin, RC | 1 |
| Atton, AV | 1 |
| de Viragh, PA | 1 |
| Gianadda, B | 1 |
| Levy, ML | 1 |
| Price, VH | 6 |
| Wasielewski, S | 1 |
| Bernard, P | 1 |
| Arnoult-Coudoux, E | 1 |
| Wiseman, MC | 1 |
| Olsen, EA | 2 |
| Carson, SC | 1 |
| Turney, EA | 1 |
| Khoury, EL | 1 |
| Abdel-Salam, MM | 1 |
| Stern, M | 1 |
| Greenspan, JS | 1 |
| Fiedler, VC | 3 |
| Wendrow, A | 2 |
| Szpunar, GJ | 1 |
| Metzler, C | 1 |
| DeVillez, RL | 2 |
| Weitzner, JM | 1 |
| Hong, D | 1 |
| Hart, LL | 1 |
| Frentz, G | 1 |
| Vestey, JP | 2 |
| Savin, JA | 2 |
| Baral, J | 2 |
| Buys, CM | 3 |
| Zaun, H | 1 |
| Kulick, MI | 1 |
| Zlotogorski, A | 1 |
| Seidenbaum, M | 1 |
| Heyman, A | 1 |
| Birnbaum, PS | 1 |
| Arndt, KA | 1 |
| Fransway, AF | 1 |
| Muller, SA | 1 |
| Fiedler-Weiss, VC | 5 |
| Shwayder, TA | 1 |
| Orecchia, G | 1 |
| Rabbiosi, G | 1 |
| Tosti, A | 1 |
| De Padova, MP | 1 |
| Minghetti, G | 1 |
| Veronesi, S | 1 |
| Clissold, SP | 1 |
| Heel, RC | 1 |
| Lenvers, P | 1 |
| Mauduit, G | 1 |
| Cambazard, F | 1 |
| Peserico, A | 1 |
| Veller-Fornasa, C | 1 |
| Paggiarin, D | 1 |
| Piva, G | 1 |
| Modugno, G | 1 |
| Cipriani, R | 1 |
| Rumsfield, J | 1 |
| Shi, YP | 1 |
| Ramelet, AA | 1 |
| White, SI | 1 |
| Friedmann, PS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial[NCT05296863] | Phase 3 | 37 participants (Actual) | Interventional | 2021-10-11 | Completed | ||
| The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study[NCT05502952] | 50 participants (Anticipated) | Interventional | 2022-07-27 | Recruiting | |||
| Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata[NCT05600673] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation[NCT03473600] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.[NCT02548689] | 10 participants (Actual) | Observational | 2015-07-31 | Terminated (stopped due to Original lead investigator left Northwestern University) | |||
| Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata[NCT04003376] | Phase 4 | 40 participants (Anticipated) | Interventional | 2019-07-26 | Recruiting | ||
| Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata[NCT03800979] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-12 | Completed | ||
| A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata[NCT01520077] | Phase 1 | 29 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil[NCT01309191] | 14 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease[NCT01981889] | Phase 4 | 53 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata[NCT00999869] | 20 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| Ocular Comorbidities of Alopecia Areata[NCT03155958] | 1 participants (Anticipated) | Observational | 2017-07-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48. (NCT03800979)
Timeframe: 48 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Dyslipidemia | Upper respiratory tract infection | Tuberculosis | Myalgia | Acne | Weight gain | Constipation | |
| Tofacitinib | 9 | 6 | 1 | 1 | 2 | 1 | 1 |
48 reviews available for minoxidil and Alopecia Circumscripta
| Article | Year |
|---|---|
Valproate-associated hair abnormalities: Pathophysiology and management strategies.
Topics: Alopecia Areata; Hair; Humans; Minoxidil; Valproic Acid | 2022 |
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Topics: Alopecia; Alopecia Areata; Female; Finasteride; Hair Follicle; Humans; Male; Minoxidil; Quality of L | 2021 |
Exploring the effects of Chinese herbal ingredients on the signaling pathway of alopecia and the screening of effective Chinese herbal compounds.
Topics: Alopecia; Alopecia Areata; China; Drugs, Chinese Herbal; Humans; Minoxidil; Plants, Medicinal; Signa | 2022 |
Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.
Topics: Alopecia; Alopecia Areata; COVID-19; COVID-19 Drug Treatment; Humans; Minoxidil; SARS-CoV-2 | 2022 |
Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.
Topics: Alopecia Areata; Humans; Lasers; Minoxidil; Phototherapy; Randomized Controlled Trials as Topic | 2023 |
Treatments for alopecia areata: a network meta-analysis.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Betamethasone; Biological Products; Child; Child, Preschoo | 2023 |
Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Female; Humans; Hypertrichosis; Male; Minoxidil; | 2020 |
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Child; Humans; Immunotherapy; Minoxidil; Patent | 2020 |
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Dendritic Cells; Humans; Immunotherapy; Janus Kinase Inhib | 2021 |
Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability.
Topics: Alopecia; Alopecia Areata; Hair; Humans; Injections; Minoxidil; Platelet-Rich Plasma; Treatment Outc | 2021 |
Telogen Effluvium - a review of the science and current obstacles.
Topics: Administration, Oral; Administration, Topical; Alopecia Areata; Anxiety; Apoptosis; Biopsy; Combined | 2021 |
Therapeutic management in paediatric alopecia areata: A systematic review.
Topics: Adolescent; Alopecia; Alopecia Areata; Child; Humans; Janus Kinase Inhibitors; Leflunomide; Minoxidi | 2021 |
Treatments for alopecia areata: A systematic review and network meta-analysis.
Topics: Alopecia Areata; Humans; Minoxidil; Network Meta-Analysis; Phototherapy; Ultraviolet Therapy | 2021 |
Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021.
Topics: Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Humans; Male; Minoxidil; Primary Health | 2021 |
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil; Monilethrix | 2021 |
Treatment for facial alopecia areata: A systematic review with evidence-based analysis.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Alopecia Areata; Anthralin; Bimatoprost; Cyclopropanes; Derma | 2018 |
Alopecia areata: An appraisal of new treatment approaches and overview of current therapies.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Alopecia Areata; Dermatologi | 2018 |
Topics: Adrenal Cortex Hormones; Alopecia Areata; Biological Products; Humans; Immunologic Factors; Janus Ki | 2018 |
Minoxidil for patchy alopecia areata: systematic review and meta-analysis.
Topics: Alopecia Areata; Humans; Minoxidil; Randomized Controlled Trials as Topic; Vasodilator Agents | 2019 |
Current treatment of alopecia areata.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Cyclobutanes; Cyclop | 2013 |
Telogen effluvium revisited.
Topics: Alopecia Areata; Antineoplastic Agents; Autoimmune Diseases; Dermoscopy; Diagnosis, Differential; Fe | 2014 |
Hair loss in children.
Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Child; Child, Preschool; Diagnosis, Differential | 2015 |
Alopecia areata.
Topics: Administration, Topical; Adrenal Cortex Hormones; Alopecia Areata; Anthralin; Autoimmunity; Cyclopro | 2015 |
Current Treatments for Alopecia Areata.
Topics: Adult; Alopecia Areata; Child; Dermatologic Agents; Holistic Health; Humans; Immunotherapy; Minoxidi | 2015 |
Diagnosing and treating hair loss.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Diagnosis, Differential; Female; Hair; Humans; M | 2009 |
Treatment of alopecia areata in children.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Alopecia Areata; Anthralin; Child; Child, Prescho | 2009 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata update: part II. Treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia Areata; Animals; Child; Cyclopropa | 2010 |
Alopecia areata.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Animals; Antibodies; Humans; Immunotherapy; Interleukins; | 2011 |
[Alopecia areata universalis due to strontium ranelate].
Topics: Aged, 80 and over; Alopecia Areata; Bone Density Conservation Agents; Drug Therapy, Combination; Fem | 2012 |
Advances in the management of alopecia areata.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Antihypertensive Agents; Biopsy; Dermoscopy; Histamine Ant | 2012 |
Alopecia in women.
Topics: Administration, Topical; Alopecia Areata; Female; Glucocorticoids; Humans; Injections, Intralesional | 2003 |
Alopecia areata: what to expect from current treatments.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alopecia Areata; Female; Haptens; Humans; Male; Minoxidi | 2005 |
Alopecia areata.
Topics: Adult; Alopecia Areata; Anthralin; Child; Dermatologic Agents; Glucocorticoids; Humans; Immunotherap | 2007 |
Minoxidil. Update on its clinical role.
Topics: Alopecia; Alopecia Areata; Female; Humans; Male; Minoxidil | 1993 |
Hair regrowth. Therapeutic agents.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Androgen Antagon | 1998 |
Treatment of hair loss.
Topics: 5-alpha Reductase Inhibitors; Administration, Topical; Alopecia; Alopecia Areata; Anthralin; Anti-In | 1999 |
[Alopecia areata: management strategy].
Topics: Adolescent; Adult; Age Factors; Alopecia Areata; Anthralin; Anti-Inflammatory Agents; Child; Humans; | 2001 |
Therapeutic approach to alopecia areata.
Topics: Administration, Topical; Adrenal Cortex Hormones; Age Factors; Algorithms; Alopecia Areata; Anthrali | 1999 |
Alopecia areata.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Alopecia Areata; Dermatitis, Contact; Dinitrochloro | 1990 |
The therapeutic use of topical minoxidil.
Topics: Administration, Cutaneous; Alopecia Areata; Drug Therapy, Combination; Female; Humans; Male; Minoxid | 1990 |
Topical minoxidil for hair loss in women.
Topics: Administration, Topical; Alopecia Areata; Dose-Response Relationship, Drug; Female; Humans; Hypertri | 1990 |
[New therapeutic aspects in non-cicatricial alopecias].
Topics: Alopecia; Alopecia Areata; Androgen Antagonists; Autoimmune Diseases; Humans; Minoxidil | 1988 |
Topical minoxidil: its use in treatment of male pattern baldness.
Topics: Administration, Topical; Alopecia Areata; Humans; Male; Minoxidil | 1988 |
[Topical minoxidil in the treatment of alopecia].
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil | 1988 |
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B | 1988 |
Minoxidil.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Animals; Cells, Cultured; Child; Clinical Trials as Topic; | 1987 |
Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil | 1987 |
[Physiopathology and treatment of alopecia areata].
Topics: Adrenal Cortex Hormones; Allergens; Alopecia Areata; Animals; Humans; Minoxidil; PUVA Therapy | 1987 |
29 trials available for minoxidil and Alopecia Circumscripta
| Article | Year |
|---|---|
Effectiveness of QR678 and QR678 Neo
Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Female; Hair; Humans; Male; Middle Aged; Minoxidil; | 2022 |
Efficacy of a mixed preparation containing piperine, capsaicin and curcumin in the treatment of alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Capsaicin; Curcumin; Humans; Minoxidil | 2022 |
Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Gels; Humans; Methotrexate; Minoxidil; Treatment | 2022 |
Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Betamethasone; Double-Blind Method; Femal | 2022 |
Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata.
Topics: Alopecia; Alopecia Areata; Humans; Injections, Intradermal; Minoxidil; Prospective Studies; Triamcin | 2022 |
Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Betamethasone | 2018 |
Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: A trichoscopic evaluation.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia Areata; Child; Dermoscopy; Egypt; Female; Hai | 2017 |
Efficacy of combination therapy for the management regime of Alopecia areata.
Topics: Adult; Alopecia Areata; Anti-Inflammatory Agents; Bangladesh; Drug Therapy, Combination; Female; Hum | 2007 |
Topical minoxidil for hair regrowth.
Topics: Administration, Topical; Adolescent; Adult; Alopecia; Alopecia Areata; Androgens; Clinical Trials as | 1984 |
[Treatment of severe alopecia areata by local administration of minoxidil].
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Female | 1984 |
Topical minoxidil in the treatment of alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Child; Clinical Trials as Topic; | 1983 |
Topical minoxidil in the treatment of alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Clinical Trials as Topic; Female; | 1984 |
Treatment of severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation.
Topics: Administration, Cutaneous; Alopecia Areata; Cyclopropanes; Double-Blind Method; Drug Combinations; G | 1995 |
Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Alopecia Areata; Child; Dermatit | 1992 |
Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; CD4-CD8 Ratio; Child; Double-Blind Method; Female; Hair; | 1992 |
Topical minoxidil in the treatment of androgenetic alopecia in women.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Female; Humans; Middle Aged; Minoxidil | 1991 |
Topical minoxidil for extended areate alopecia.
Topics: Adolescent; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1985 |
A trial of 1% minoxidil used topically for severe alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Clinical Trials as Topic; Double-Blind Method; Fema | 1986 |
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B | 1988 |
Minoxidil.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Animals; Cells, Cultured; Child; Clinical Trials as Topic; | 1987 |
Topical minoxidil for baldness.
Topics: Administration, Cutaneous; Alopecia; Alopecia Areata; Clinical Trials as Topic; Humans; Male; Minoxi | 1987 |
Natural history of severe alopecia areata.
Topics: Alopecia Areata; Clinical Trials as Topic; Follow-Up Studies; Humans; Minoxidil; Ointments | 1987 |
Therapies versus placebo in the treatment of patchy alopecia areata.
Topics: Adolescent; Adult; Age Factors; Aged; Alopecia Areata; Child; Child, Preschool; Clinical Trials as T | 1986 |
Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Double-Blind Metho | 1987 |
Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Double-Blind Metho | 1987 |
Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Double-Blind Metho | 1987 |
Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Child; Clinical Trials as Topic; Double-Blind Metho | 1987 |
Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy.
Topics: Administration, Topical; Alopecia Areata; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1987 |
Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata.
Topics: Administration, Topical; Alopecia Areata; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1987 |
Topical minoxidil in extensive alopecia areata, including 3-year follow-up.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia Areata; Child; Dermatitis, Contact; Double-Bl | 1987 |
Topical minoxidil in the treatment of alopecia areata and male-pattern alopecia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Female; Humans; | 1986 |
Topical minoxidil lacks efficacy in alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Female; Humans; Male; Middle Aged | 1985 |
55 other studies available for minoxidil and Alopecia Circumscripta
| Article | Year |
|---|---|
Systemic minoxidil as maintenance treatment in alopecia areata: a retrospective case series of 24 patients.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Hair; Humans; Immunotherapy; Minoxidil; Retrospe | 2022 |
Oral minoxidil use in androgenetic alopecia and telogen effluvium.
Topics: Adult; Aged; Alopecia; Alopecia Areata; Female; Humans; Male; Middle Aged; Minoxidil; Retrospective | 2023 |
Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study.
Topics: Alopecia; Alopecia Areata; Child; Humans; Minoxidil | 2022 |
Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata.
Topics: Alopecia Areata; Anthralin; Biological Products; Cross-Sectional Studies; Decision Making; Emotions; | 2022 |
Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp.
Topics: Alopecia; Alopecia Areata; Glycyrrhizic Acid; Humans; Lipedema; Minoxidil; Scalp; Vitamin D | 2022 |
Allergic Contact Dermatitis Due to Minoxidil in a Patient with Alopecia Areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Dermatitis, Allergic Contact; Humans; Minoxidil; | 2022 |
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
Topics: Alopecia; Alopecia Areata; Hair; Humans; Minoxidil; Quality of Life | 2023 |
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines | 2021 |
Efficacy and Influence Factors of 308-nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata.
Topics: Alopecia; Alopecia Areata; Female; Hair; Humans; Lasers, Excimer; Male; Minoxidil; Prospective Studi | 2020 |
Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Topics: Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines; Pyrroles | 2021 |
Current Treatment of Alopecia Areata.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Alopecia Areata; Clinical Decision-Making; Clini | 2020 |
Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Child; Child, Preschool; Dermatolog | 2018 |
Treatment of alopecia areata: An Australian expert consensus statement.
Topics: Alopecia Areata; Autoimmune Diseases; Disease Progression; Down Syndrome; Glucocorticoids; Humans; I | 2019 |
Allergic contact dermatitis probably caused by latanoprost during treatment for alopecia areata.
Topics: Administration, Cutaneous; Alopecia Areata; Dermatitis, Allergic Contact; Facial Dermatoses; Female; | 2019 |
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Child; Combined Modality Therapy; Female; | 2019 |
Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy.
Topics: Administration, Topical; Alopecia Areata; Child; Female; Hair Removal; Humans; Hypertrichosis; Laser | 2013 |
Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Alopecia Areata; Black or Afr | 2015 |
Clinical characteristics and HLA alleles of a family with simultaneously occurring alopecia areata.
Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Anxiety; Child; Compulsive Personality Disorder; Cr | 2016 |
A case of patchy alopecia areata sparing lesional greying hairs.
Topics: Acute Disease; Alopecia Areata; China; Hair Color; Humans; Hypopigmentation; Male; Middle Aged; Mino | 2008 |
Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe.
Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Anticholesteremic Agents; Drug Therapy, Combination | 2010 |
Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman.
Topics: Adult; Alopecia Areata; Betamethasone; Drug Therapy, Combination; Female; Humans; Minoxidil; Tinea C | 2010 |
Clinical inquiries: childhood alopecia areata: what treatment works best?
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Alopecia Areata; Child; Ch | 2011 |
Alopecia Areata: a possible extraintestinal manifestation of Crohn's disease.
Topics: Adult; Alopecia Areata; Anti-Inflammatory Agents; Clobetasol; Crohn Disease; Female; Humans; Minoxid | 2012 |
Information from your family doctor. Hair loss in women.
Topics: Alopecia Areata; Female; Hair; Humans; Minoxidil | 2003 |
[Hair loss].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Biopsy; Child; Clinical Tria | 2003 |
Guidelines for the management of alopecia areata.
Topics: Alopecia Areata; Anthralin; Counseling; Evidence-Based Medicine; Glucocorticoids; Humans; Immunother | 2003 |
Alopecia areata masquerading as frontal fibrosing alopecia.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Biopsy, Needle; Dermatologic Agents; Diagnosis, | 2006 |
Topical use of minoxidil in children and systemic side effects.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Cardiovascular Diseases; Child; Female; Follow | 2007 |
Traction alopecia: 2% topical minoxidil shows promise. Report of two cases.
Topics: Administration, Topical; Alopecia Areata; Black or African American; Cosmetic Techniques; Female; Hu | 2007 |
Alopecia areata.
Topics: Adult; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; M | 2007 |
Alopecia areata: pathogenesis and treatment.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Autoimmune Diseases; Complement System Proteins; Diseases | 1984 |
Topical minoxidil in the treatment of alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Child; Child, Preschool | 1983 |
Topical minoxidil in the treatment of alopecia areata.
Topics: Adult; Alopecia Areata; Female; Humans; Male; Minoxidil; Pyrimidines | 1984 |
Alopecia areata treated with topical minoxidil.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Child; Female; Hair; Humans; Male | 1984 |
Alopecia areata treated with tropical minoxidil.
Topics: Administration, Topical; Aged; Alopecia Areata; Female; Humans; Middle Aged; Minoxidil; Pyrimidines | 1982 |
Topical minoxidil in alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Female; Humans; Minoxidil; Pyrimidines | 1981 |
Alopecia areata, topical minoxidil, and balanced reviews.
Topics: Administration, Cutaneous; Alopecia Areata; Humans; Minoxidil | 1993 |
Congenital alopecia areata.
Topics: Alopecia Areata; Epidermis; Female; Follow-Up Studies; Hair; Hair Follicle; Humans; Infant, Newborn; | 1997 |
[Treatment for hair loss].
Topics: Alopecia; Alopecia Areata; Female; Finasteride; Humans; Male; Minoxidil | 2000 |
Evidence-based treatment of alopecia areata.
Topics: Administration, Oral; Administration, Topical; Alopecia Areata; Anthralin; Anti-Inflammatory Agents; | 2001 |
Alopecia areata: current therapy.
Topics: Alopecia Areata; Betamethasone; Drug Therapy, Combination; Humans; Minoxidil; T-Lymphocytes, Cytotox | 1991 |
Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin.
Topics: Administration, Topical; Adolescent; Adult; Alopecia Areata; Anthralin; Child; Drug Combinations; Dr | 1990 |
Minoxidil and tail-like effect.
Topics: Alopecia Areata; Child, Preschool; Female; Humans; Hypertrichosis; Minoxidil | 1989 |
Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment.
Topics: Adolescent; Adult; Alopecia Areata; Child; Female; Humans; Immunoenzyme Techniques; Langerhans Cells | 1987 |
Alopecia: common and uncommon.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Min | 1986 |
Symposium on alopecia areata.
Topics: Alopecia Areata; Child; Humans; Minoxidil | 1988 |
Patterns of hair regrowth in alopecia areata.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Alopecia Areata; Child; Cyclobutanes; Cyclopropanes; Fema | 1988 |
Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation.
Topics: Adolescent; Adult; Alopecia Areata; Autoantibodies; Child; Female; Humans; Lymphocyte Activation; Ma | 1987 |
Rogaine (topical minoxidil, 2%) in the management of male pattern baldness and alopecia areata. Proceedings of a symposium. Palm Beach, FL, May 17, 1986.
Topics: Alopecia; Alopecia Areata; Humans; Male; Minoxidil | 1987 |
Potential mechanisms of minoxidil-induced hair growth in alopecia areata.
Topics: Alopecia Areata; Animals; Dose-Response Relationship, Drug; Hair; Humans; Lymphocytes; Mice; Minoxid | 1987 |
[Minoxidil in the local treatment of alopecia areata and of androgenous alopecia].
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Drug Evaluation; Humans; Male; Minoxidil | 1986 |
[Topical minoxidil in the treatment of alopecia areata: dose-dependent response].
Topics: Administration, Topical; Alopecia Areata; Dose-Response Relationship, Drug; Female; Humans; Male; Mi | 1987 |
Minoxidil and tail-like effect.
Topics: Administration, Topical; Alopecia Areata; Child, Preschool; Female; Hair; Humans; Minoxidil | 1987 |
Evaluation of oral minoxidil in the treatment of alopecia areata.
Topics: Administration, Oral; Administration, Topical; Adult; Alopecia Areata; Dose-Response Relationship, D | 1987 |
Minoxidil induces selective regrowth of androgenetic dependent hair.
Topics: Adult; Alopecia Areata; Androgens; Hair; Humans; Male; Minoxidil | 1986 |